Cardiovascular · Beta-blockerRegulatory Approvalcommercialnear-term

FDA Grants Approval for Propranolol Hydrochloride ANDA219165

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 6:32:30 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of PAI Holdings' ANDA for Propranolol Hydrochloride introduces a generic competitor into the beta-blocker market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the potential impact on existing propranolol products and adjust strategies accordingly. Regulatory context from FDA (FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this generic entry on pricing and market share for existing propranolol products. The strongest clinical anchor is Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular · Beta-blocker, 8 regulatory and 2 competitive items passed relevance filtering for Propranolol Hydrochloride.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement (Humanexa Signals) — sponsor/company relevance (pfizer). Secondary pressure from FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals. This approval allows PAI Holdings to market a generic version of Propranolol, potentially increasing competition in the beta-blocker market.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG) (FDA). Entity match (propranolol hydrochloride); Regulatory pathway relevance (nda). The approval signifies compliance with FDA standards but does not introduce significant regulatory changes for existing products.

Key Opportunities

The entry of a generic version may lead to price reductions and increased competition, affecting revenue and market share for branded propranolol products.
Portfolio teams should assess the impact of this generic entry on pricing and market share for existing propranolol products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies from PAI Holdings and competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (propranolol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (propranolol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (propranolol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROXYZINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VALACYCLOVIR HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DORZOLAMIDE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and Mechanism of 'Yanjiu Needle' for Pharyngeal Dysphagia Based on sEMG Features
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment

Oral propranolol treatment safety in infantile hemangiomas.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Electroacupuncture for essential hypertension: Mechanistic insights, current clinical evidence, and translational challenges.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Propranolol Hydrochloride

Commercial impact

medium

The entry of a generic version may lead to price reductions and increased competition, affecting revenue and market share for branded propranolol products.

Regulatory impact

low

The approval signifies compliance with FDA standards but does not introduce significant regulatory changes for existing products.

What to watch

Monitor market entry timelines and pricing strategies from PAI Holdings and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.